Rise in Death Toll due to COVID-19 Pandemic to Boost Sales in Non-Small Cell Lung Cancer Therapeutics Market

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=504

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Request For Covid19 Impact Analysis –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=504

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

Buy Report Now : https://www.transparencymarketresearch.com/checkout.php?rep_id=504&ltype=S

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

This analysis of the global non-small cell lung cancer market is based on a recent market research report by Transparency Market Research, titled “Non-Small Cell Lung Cancer Therapeutics Market (Pipeline – Early Stage (Phase I and II) and Late Stage (Phase III); Drug Class – Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Read our Case study at : https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

For the study, the market has been segmented as follows:

Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)Overview
Angiogenesis InhibitorAvastin (bevacizumab)
Cyramza (Ramucirumab)
Epidermal Growth Factor Receptor BlockerTarceva (erlotinib)
Gilotrif (afatinib)
Iressa (gefitinib)
Kinase InhibitorXalkori (crizotinib)
Zykadia (ceritinib)
Microtubule StabilizerAbraxane (paclitaxel protein bound)
Docetaxel
Folate AntimetabolitesAlimta (pemetrexed)
PD-1/ PD-L1 InhibitorOpdivo (nivolumab)
Keytruda (pembrolizumab)
Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics MarketOverview
Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)Avelumab – Pfizer, Inc.
MPDL3280A – Roche
MEDI4736 – AstraZeneca
Abemaciclib – Eli Lilly and Company
Others
Early Stage (Phase I and II) (Qualitative Analysis – Tabular representation)
Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)Overview
North AmericaU.S.
Canada
EuropeU.K.
Germany
Rest of Europe
Asia PacificJapan
China
Rest of Asia Pacific
Rest of the World